Showing results (111-120 of 137) with videos related to

Sort By:
Pageof 14
BMC Cancer|September 15, 2020
Lutetium-177-PSMA-I&T as metastases directed therapy in oligometastatic hormone sensitive prostate cancer, a randomized controlled trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
European Urology|April 25, 2016
Detection of High-grade Prostate Cancer Using a Urinary Molecular Biomarker-Based Risk ScoreLeander Van Neste, Rianne J Hendriks, Siebren Dijkstra, et al.
British Journal of Cancer|November 1, 2025
Molecular reflex testing in patients with early metastatic castration-resistant prostate cancer within the PROMPT-studyIris S H Kloots, Peter H J Slootbeek, Sofie H Tolmeijer, et al.
The Lancet. Oncology|April 2, 2026
[177Lu]-PSMA-617-PSMA-617 in oligometastatic hormone sensitive prostate cancer (BULLSEYE): an open-label, randomised, phase 2 studyBastiaan M Privé, Walter Noordzij, Constantijn H J Muselaers, et al.
Drugs - Real World Outcomes|March 22, 2022
Being Transparent About Brilliant Failures: An Attempt to Use Real-World Data in a Disease Model for Patients with Castration-Resistant Prostate CancerMarscha S Holleman, Simone A Huygens, Maiwenn J Al, et al.
European Urology Focus|November 22, 2019
Variation in the Prescription of Androgen Deprivation Therapy in Intermediate- and High-risk Prostate Cancer Patients Treated with Radiotherapy in the Netherlands, and Adherence to European Association of Urology Guidelines: A Population-based StudyBarbara Lily Thérèse Rijksen, Floris J Pos, Maarten C C M Hulshof, et al.
Clinical Genitourinary Cancer|December 30, 2019
Health-related Quality of Life and Pain in a Real-world Castration-resistant Prostate Cancer Population: Results From the PRO-CAPRI Study in the NetherlandsMalou C P Kuppen, Hans M Westgeest, Alphonsus J M van den Eertwegh, et al.
Trials|November 5, 2021
Update to a randomized controlled trial of lutetium-177-PSMA in Oligo-metastatic hormone-sensitive prostate cancer: the BULLSEYE trialBastiaan M Privé, Marcel J R Janssen, Inge M van Oort, et al.
Drugs - Real World Outcomes|May 9, 2026
From Genomic Testing to Olaparib Treatment: Real-World Utilization and Outcomes in BRCA-Mutated Metastatic Castration-Resistant Prostate CancerDianne Bosch, Kim J M van der Velden, Aart Beeker, et al.
European Urology|July 15, 2026
EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines on Prostate Cancer-2026 Update. Part I: Screening, Diagnosis, and Local Treatment with Curative IntentPhilip Cornford, Roderick C N van den Bergh, Erik Briers, et al.
Pageof 14